Bissonnette R, et al. - With regard to the treatment of moderate to severe psoriasis, experts sought to assess the effectiveness and safety of secukinumab. They noted high and sustained levels of skin clearance and better quality of life through 5 years by secukinumab 300 mg treatment. Secukinumab phase 2/3 program established favorable safety which was maintained for 5 years.